Asia Pacific
Refine Search
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Biotechnology
Japan’s Nxera Pharma – formerly known as Sosei – and Antiverse, a UK techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). 5 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Pharmaceutical
Japanese pharma major Takeda today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. 31 October 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
Takeda has release positive interim results from a Phase III-enabling proof-of-concept study for mezagitamab (TAK-079), a potential best-in-class anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN). 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Pharmaceutical
Corxel Pharmaceuticals and LENZ Therapeutics have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100. 29 October 2024
Pharmaceutical
Japanese drugmaker Shionogi saw its shares rise 2.3% to 2,173 yen today after it released positive research findings. 29 October 2024
Biotechnology
Yongyin-based biopharma company GC Biopharma has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA). 28 October 2024
Pharmaceutical
Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). 28 October 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Pharmaceutical
Japan-based Sosei Group’s shares rose 8.4% to 2,222 yen today, as it announced it is collaborating with US pharma major Eli Lilly to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets linked with diabetes and metabolic diseases. 16 December 2022
Biotechnology
Announcing further plans to accelerate and broaden the clinical development of its cancer immunotherapy pipeline in the Asia-Pacific region, Germany’s BioNTech said that the first regional clinical trial sites for the company’s mRNA-based cancer immunotherapies are planned to be activated in Taiwan to initially evaluate BioNTech’s cancer product candidate BNT113 against head and neck cancer. 16 December 2022
Biotechnology
Japanese drugmaker Takeda has put plenty on the line to acquire NDI-034858 from privately-held US drug discovery company Nimbus Therapeutics. 13 December 2022
Pharmaceutical
Providing further evidence that generics major Viatris is pushing wider beyond copy drugs, the company has entered into an exclusive license agreement with Sweden’s Calliditas Therapeutics to register and commercialize the latter’s Nefecon in Japan. 13 December 2022
Biotechnology
Japanese drug major Daiichi Sankyo’s shares edged up nearly 2% to 4,426 yen today, after it announced it was giving up Japanese marketing rights to Yescarta (axicabtagene ciloleucel). 8 December 2022
Biotechnology
Shares of US drugmaker Summit Therapeutics went stratospheric yesterday, rocketing 194% to $2.31 by close, after it announced a licensing deal with a Chinese drug developer that could cost it as much as $5 billion. 7 December 2022
Biotechnology
Shares of La Jolla USA-based biotech Equillium were up 12% to $1.85 in pre-market trading, on news of a lucrative licensing deal with Japan’s Ono Pharmaceutical. 6 December 2022
Generics
Swiss contract development and manufacturing organization (CDMO) Lonza today announced the start of new mid-scale manufacturing assets at its active pharmaceutical ingredients (API) manufacturing center in Nansha, China. 5 December 2022
Biotechnology
Having invented the concept, it is odd that China should have been so behind in making medicine for so long. That has changed: the Chinese pharmaceutical market is now the second biggest in the world, and for many years the Chinese state has been driving towards the enormous opportunities that a firmer grip on this drug development could bring, according to a report from McKinsey & Co. 3 December 2022
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (ICER) today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of Japanese pharma major Astellas’ fezolinetant for the vasomotor symptoms (VMS) associated with menopause, finding the evidence for drug promising but inconclusive. 1 December 2022
Pharmaceutical
An Expert View from Neelam Patel, chief executive of London life sciences cluster organization MedCity, which led the recent UK delegation to BioJapan 2022, exploring why Japan is such an important partner for the UK and future areas of opportunity. 29 November 2022
Pharmaceutical
Australian CSL Limited’s recently-incorporated Swiss business CSL Vifor and its partner Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject (ferric carboxymaltose). 28 November 2022
Pharmaceutical
The Medicines for Malaria Venture (MMV) and Shin Poong Pharm have welcomed the formal inclusion of Pyramax (pyronaridine-artesunate), developed by the South Korean company, in the World Health Organization’s (WHO) Guidelines for Malaria following an extensive review process. 25 November 2022
Pharmaceutical
Japanese drugmaker Shionogi (TYO: 4507) said yesterday that its Xocova (ensitrelvir fumaric acid, Code No.: S-217622), a novel anti-SARS-CoV-2 drug for COVID-19 obtained emergency regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the indication of SARS-CoV-2 infection. 23 November 2022
Biotechnology
Investing in early-stage multicenter trials is imperative to achieve global commercialization for Chinese biotechs, but a US site may not be necessary, said speakers at the Chinatrials meeting held in Shanghai earlier this month. 21 November 2022
Biotechnology
Japanese drug major Takeda today revealed that the Phase III PhALLCON trial of Iclusig (ponatinib) for adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) met its primary efficacy endpoint in the frontline setting. 17 November 2022
Biotechnology
Japanese drug major Astellas Pharma today announced positive top-line results from the Phase III SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab in combination with mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil). 17 November 2022
Biotechnology
Swiss biotech Idorsia has entered into an exclusive licensing agreement with China’s Simcere Pharmaceutical for the commercialization of its dual orexin receptor antagonist daridorexant, a treatment for adult patients with insomnia, in China. 16 November 2022
Biotechnology
Japanese drugmaker Daiichi Sankyo edged up 1.7% to 4,486 yen today, as it announced that a trial evaluating the efficacy and safety of booster vaccination with DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19), the primary endpoint was achieved. 15 November 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze